Myriad Genetics slips on patent concerns

Shares of Myriad Genetics Inc. fell Wednesday after a Supreme Court ruling started a new round of concerns about the company's intellectual property, which includes patents on genetic mutations related to breast cancer. The spark was on Tuesday when the Supreme Court threw out patent claims belonging to Prometheus Laboratories, a subsidiary of Nestle SA. The 9-0 ruling overturned patents that were used in a blood test that helps doctors determine the dosage of a drug used to treat autoimmune diseases...
Flag this


There are currently no comments. Add a new comment!

Post a comment

You must be logged in to post comments. Login now

Posted by Mike Spear


I am the Communications Director for Genome Alberta and we manage this application. In my past life I was a journalist and manager with the CBC. You can find my genome posted at

0 people like this

Be the first to like this